MedTrace Logo

Abscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity

NCT04722354 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-03-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effects of oral abscisic acid (ABA) on glucose metabolism in subjects with defined prediabetes.

Conditions

  • Pre Diabetes

Interventions

OTHER

Hyperinsulemic euglycemic clamp

Following a 12-hour overnight fast at the CRU (including abstinence from caffeine containing foods and beverages), insulin sensitivity will be measured using the criterion method of the euglycemic clamp. Participants will have not performed vigorous physical activity for at least the previous 24 h, and be free of acute illness for the prior 2 weeks. An intravenous catheter will be placed in an antecubital vein for subsequent insulin (40 mU/m2-min) and glucose infusions and for stable isotope (6, 6-2H2) infusions to measure insulin sensitivity.

PROCEDURE

Muscle Biopsy

One biopsy taken prior to clamp and a second biopsy taken 30-45 min after the start of the clamp. A biopsy of the Vastus Lateralis muscle will be performed on the leg/thigh using the Bergstrom technique.

DIETARY_SUPPLEMENT

Oral abscisic acid (ABA)

Those in this group will receive ABA (95 µg ABA and 300 mg of corn starch)

OTHER

Placebo

Those in this group will receive placebo (300 mg cornstarch)

Sponsors & Collaborators

  • BioTherapeutics Inc.

    collaborator INDUSTRY

  • AdventHealth Translational Research Institute

    lead OTHER

Principal Investigators

  • Bret Goodpaster, PhD · Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-08
Primary Completion
2024-08-26
Completion
2025-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04722354 on ClinicalTrials.gov